Philips' Net Income Dips 47% in Q2 2025

For the second quarter of 2025, Koninklijke Philips N.V. reported sales of EUR 4.3 billion, marking a 3% decrease from EUR 4.46 billion in Q2 2024. Net income for the quarter stood at EUR 240 million, a significant 47% decline compared to EUR 452 million in the same period last year. The decline in net income was primarily due to the comparative impact of EUR 538 million in insurance income related to Respironics product liability claims recorded in Q2 2024.

Performance Against Estimates

The reported revenue of EUR 4.3 billion was below the analyst estimate of EUR 4.33 billion. Diluted earnings per common share from continuing operations attributable to shareholders were EUR 0.25, missing the analyst EPS estimate of EUR 0.2907.

Segment Performance

Comparable order intake growth sequentially improved to 6%, supported by recently launched AI-powered innovations. The Adjusted EBITA margin increased by 130 basis points to 12.4%, driven by higher gross margin from innovation, product mix, and productivity measures. Free cash flow increased to EUR 230 million.

Key Business Drivers

Personal Health sales increased 6% across most geographies, although this was partly offset by a decline in China. Diagnosis & Treatment and Connected Care comparable sales each decreased by 1%. This was on the back of a high comparison base in prior years due to supply chain improvements.

Management Outlook

Royal Philips reiterated its full-year 2025 comparable sales growth outlook in the range of 1%-3%, with sequential improvement anticipated as the year progresses. The company increased its full-year Adjusted EBITA margin outlook to 11.3%-11.8%, a 50 basis point increase from the previous outlook. Free cash flow for the full year is now expected to be between EUR 0.2 billion and EUR 0.4 billion.